Abstract Chronic lymphocytic leukemia (CLL) is frequently associated with autoimmune complications such as autoimmune hemolytic anemia, immune thrombocytope nia, pure red cell aplas ia, a nd autoimmun e granulocytopenia. It is critical to diagnose cytopenias from these secondary complications of CLL accurately, since prognosis and therapy are substantially different from patients who have cytopenias due to extensive bone marrow infiltration by CLL. The pathogenesis of autoimmune cytopenias in CLL is complex; and it involves antigen presentation by CLL cells to polyclonal B cells resulting in production of autoantibody, and alteration of the T cell milieu tilting the balance in favor of an autoimmune response. Traditional therapy of autoimmune complications in CLL consists of immunosuppression with corticosteroids and/or anti-CD20 monoclonal antibodies. In patients who have a suboptimal response, treating the underlying CLL is generally effective in ameliorating secondary cytopenias. Although novel oral therapies such as ibrutinib, idelalisib, and venetoclax have been shown to be extremely effective in the management of CLL, prospective data from larger numbers of patients with longer follow-up are needed prior to recommending their routine use in the management of autoimmune cytopenias in CLL.
Introduction
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the Western world [1] , with an estimated incidence of 4.5 cases per 100,000 individuals annually in the USA [2] . Patients with CLL are at an increased risk of infections and non-hematologic malignancies, due to profound defects in their immune system. Although hypogammaglobulinemia is the most commonly reported immune defect in CLL [3] , abnormalities of T cells, NK-cells, monocytes, and neutrophils all contribute to these secondary events [4] [5] [6] [7] [8] . Paradoxically, there also appears to be a significant proportion of CLL patients who are at risk for autoimmune cytopenias during the course of their disease. In this review, we will focus on the epidemiology, pathogenesis, diagnosis, treatment, and outcome of patients with autoimmune cytopenias in CLL.
Epidemiology
Autoimmune cytopenias occur in approximately 4-10% patients with CLL, although the exact incidence may be difficult to determine because these can precede CLL diagnosis and present at any time of disease [9] [10] [11] . Autoimmune hemolytic anemia (AIHA) is the most common type of autoimmune cytopenia and involves antibody-mediated red blood cell destruction. Immune thrombocytopenia (ITP) is the second most common and involves antibody-mediated platelet destruction [12] . Pure red cell aplasia (PRCA) and autoimmune This article is part of the Topical Collection on Chronic Lymphocytic Leukemias granulocytopenia (AIG) are relatively rare and occur in <1% patients [13] . PRCA develops due to an immune-mediated destruction of red cell precursors and manifests as reticulocytopenia and anemia. AIG involves an immunemediated destruction of myeloid precursors, and presents as isolated granulocytopenia with an otherwise unremarkable complete blood count.
In a study of 1750 CLL patients observed over 10 years at the Mayo Clinic, autoimmune cytopenias were diagnosed in 75 (4.3%) patients. AIHA occurred most commonly (2.3%), followed by ITP (2.0%), PRCA (<0.5%), and AIG (<0.5%) [14] . In another large retrospective study (n = 960), autoimmune cytopenias were diagnosed in 7% of patients (27% were detected at time of CLL diagnosis, 4% preceding the diagnosis of CLL, and 68% during the course of disease). In these patients, AIHA occurred in 5% of patients, ITP in 2% of patients, and Evans syndrome (concomitant AIHA and ITP) in 0.1% [9] . These data indicate that ∼1 out of every 16 CLL patients will have autoimmune cytopenias during the course of their disease, and practicing clinicians need to be cognizant about recognizing and managing them appropriately.
Pathophysiology of Autoimmune Cytopenias in CLL
Autoimmune cytopenias associated with CLL are believed to occur by a variety of complex mechanisms, which have recently been well-reviewed [15, 16] . Secondary autoimmune cytopenias in the setting of CLL are primarily due to nonmalignant B cells producing polyclonal high-affinity immunoglobulin G (IgG) antibodies that are directed against antigens on red blood cells and platelets that lead to hemolytic anemia and immune thrombocytopenia, respectively [17] . These antibodies can also be directed against maturing erythroblasts and granulocyte precursors in the bone marrow, resulting in PRCA and AIG, respectively [18] . CLL B cells are known to produce IgM autoimmune antibodies which can lead to intravascular hemolysis in a small proportion of patients. Additionally, CLL cells produce several cytokines that can result in inhibition of normal erythropoiesis or megakaryopoiesis, leading to the development of AIHA and ITP [16] . The T cell compartment is significantly altered in CLL patients; while this can increase the risk of infections, it also contributes to the development of autoimmune complications. T regulatory cells (T regs ), which play a role in suppression of immune responses, are shown to be abnormally increased in CLL patients [19] . A more recent study demonstrated that T helper 17 cells (T H 17 cells) are associated with an increased incidence of autoimmune cytopenias in CLL, and that an imbalance in the ratio between T H 17 cells and T regs leads to development of autoimmune cytopenias in CLL patients [20] . It is hoped that with the advent of newer technologies such as mass cytometry [21] , we will be better able to define the specific types of T cell subsets that contribute to autoimmune cytopenias in CLL.
It is well known that the immunoglobulin heavy chain variable region (IGHV) mutational status influences clinical outcome in CLL patients. CLL patients whose IGHV genes are mutated (>2% deviation from the germline sequence) have a longer progression-free survival (PFS) and longer overall survival (OS) compared to patients who have unmutated IGHV genes [22] . Patients who have autoimmune cytopenias are more likely to have unmutated IGHV genes compared to those who do not have autoimmune cytopenias [14] ; it is possible that the B cell receptor on the surface of CLL cells with unmutated IGHV is more prone to stimulation by erythrocyte antigens causing activation and autoantibody production. Another mechanism of autoimmune complications in CLL is a result of abnormal expression of toll-like receptors (TLRs). Reduced TLR4 activity specifically was associated with an increased risk of autoimmune complications in CLL patients. However, reduced TLR4 expression was more evident in patients with advanced disease and unmutated IGHV, and the relative contribution of reduced TLR activity in the contribution of CLL remains unclear [23] .
Finally, CLL therapy can induce autoimmune cytopenias, particularly AIHA. Single-agent purine analog therapy (such as fludarabine) is known to induce hemolytic anemia in CLL patients [24, 25] . Patients who have received multiple prior therapies appear to be at a higher risk for this complication. The exact mechanism by which fludarabine induces hemolysis is unclear, but it is likely secondary to an alteration in the peripheral blood T H 17/T reg ratio in these patients [26] . While single-agent fludarabine therapy is contraindicated in patients with hemolytic anemia, combination chemoimmunotherapy such as fludarabine, cyclophosphamide, and rituximab (FCR) may not cause a similar degree of hemolysis. In the CLL8 trial [27] that randomized previously untreated CLL patients to either FCR or fludarabine and cyclophosphamide (FC), there was no difference in the incidence of hemolytic anemia in the two arms (<1%). However, it is unclear what proportion of patients had a history of autoimmune hemolytic anemia prior to starting FCR or FC therapy on the CLL8 trial. In our practice, we avoid using s i n g l e -a g e n t f l u d a r a b i n e a n d c o m b i n a t i o n chemoimmunotherapy in patients who have a history of severe hemolysis in the past. In patients with history of severe hemolysis in the past, and in whom chemoimmunotherapy is contemplated, therapy with bendamustine and rituximab (BR) is well tolerated and does not induce significant hemolysis. In a series of 64 refractory CLL patients [28] who were treated with lowdose alemtuzumab (defined as a total weekly dose of <45 mg or cumulative dose of <600 mg), 6 (9%) patients developed treatment-emergent ITP. This was hypothesized to be due to alemtuzumab's role in T cell dysregulation, leading to increased autoimmunity. Bendamustine-based therapy is also associated with autoimmune cytopenias in CLL, particularly PRCA [29] .
Autoimmune Hemolytic Anemia
A suggested approach to a CLL patient with anemia is shown in Fig. 1 . Anemia in CLL may be due to various etiologies, such as bone marrow failure, bleeding, vitamin or iron deficiencies, anemia of renal disease, anemia of inflammation, and autoimmune hemolytic anemia. A diagnosis of AIHA can be made if the following criteria are met [10, 16, 30, 31] :
-Hb <11 gm/dL, in the absence of any cytotoxic therapy in the preceding month or other identified etiology -At least one laboratory sign of hemolysis: such as increased unconjugated bilirubin without liver disease, elevated lactate dehydrogenase (LDH) without alternative cause, reduced haptoglobin, and increased absolute reticulocyte count in the absence of bleeding -Direct or indirect evidence of an autoimmune process, such as positive direct antiglobulin test (DAT) for either IgG or C3d, or cold agglutinins
Unfortunately, the diagnosis of AIHA can be difficult to make in the setting of CLL because the laboratory values for hemolysis may be distorted in CLL due to disease progression or therapy. For example, LDH levels may be elevated because of disease progression; haptoglobin levels may be elevated as an acute phase response; and reticulocytosis may not be present in patients who have decreased bone marrow production because of prior therapy or bone marrow infiltration [16] . Although DAT can be an important diagnostic tool in the approach to AIHA, its positivity does not necessarily predict whether CLL patients will develop AIHA [32] . In a study of 36 Binet stage A CLL patients who had a positive DAT at baseline, ∼1/3 of the patients developed the clinical manifestations of AIHA during follow-up [32] . To complicate matters in the interpretation of DAT, there are reports of DAT negative AIHA in CLL patients [16, 33] . These are thought to be associated with the presence of low-affinity autoantibodies or to a number of RBC-bound IgG molecules that is below the threshold of positivity for the test [16] . In such cases, more sensitive testing may be required, such as using microcolumn and solid-phase tests, or other sophisticated techniques, such as mitogen-stimulated DAT. These tests are thought to detect up to 30 to 40 molecules of anti-RBC autoantibodies [16] , thereby leading to identification of more cases of CLLassociated AIHA (30%) compared to 4% when using standard DAT [34] . Considering the many caveats of laboratory testing for anemia in CLL patients, and after exclusion of secondary causes of anemia, a bone marrow biopsy may become necessary to document the extent of CLL infiltration or to investigate other reasons for anemia (including myelodysplastic syndrome).
Patients presenting with acute anemia should initially be managed based on their hemoglobin level and symptoms; blood transfusions are required for symptomatic patients with severe anemia. For AIHA due to warm antibodies, first-line therapy is prednisone at 1 mg/kg per day for 3-4 weeks, which may be slowly tapered off during the following 1-2 months. An alternative regimen is pulsed high-dose dexamethasone (40 mg for four consecutive days), although this would need further investigation for use in secondary autoimmune cytopenias in CLL. For patients with secondary AIHA who present with significant hemolysis, intravenous immunoglobulin infusion (IVIg) at 1 gm/kg on days 1 and 2 may also be used [16, 35] . Patients who have secondary AIHA due to cold antibodies often have a milder presentation. The decision to treat them should be reserved for patients who have transfusiondependent symptomatic anemia or symptoms secondary to cold agglutinin disease. Corticosteroids are generally not as effective in these patients, as opposed to those with AIHA due to warm antibodies. In these patients, rituximab is generally considered the first-line treatment option. At doses of 375 mg/ m 2 weekly for 4 weeks, rituximab has been shown to be effective and well-tolerated, with objective responses seen in approximately 70-100% of patients [35] [36] [37] . A similar approach can be used in steroid refractory warm antibodymediated AIHA in CLL. Use of lower doses of rituximab at 100 mg/m 2 for four weekly infusions in conjunction with steroids has been studied only in primary AIHA, although a similar strategy could be used in CLL patients with AIHA [38] . Newer generation monoclonal antibodies such as ofatumumab and obinutuzumab may also be used in secondary AIHA [39] . Although alemtuzumab has been used in this circumstance [40] , we do not recommend its use because of the potential to cause severe infectious complications. If there is no response to corticosteroids within 4-6 weeks, or if response is not prolonged, then alternative therapies such as mycophenolate mofetil, cyclosporine, cyclophosphamide, and azathioprine could be considered [41] .
In many instances, treatment of the underlying CLL becomes essential in controlling the AIHA accompanying CLL (Table 1 ). There are several potential treatment options in this situation. Therapy with BR has been shown to be a safe and effective therapy in patients with AIHA secondary to CLL, refractory to other therapies, who also required control of their progressive CLL. In a study of 26 CLL patients treated with BR [42] , the overall response rate was 81% for AIHA and 77% for CLL with a median time to next treatment of 28 months for AIHA and 26 months for CLL. In a study of eight CLL patients who had steroid refractory A I H A [ 4 3 ] , t h e c o m b i n a t i o n o f r i t u x i m a bcyclophosphamide-dexamethasone (RCD) was shown to have an overall response rate of 89% and a complete response rate of 83%. The median duration of response was 24 months and was dependent on the type of autoimmune cytopenia-it was shorter for patients with Evans syndrome and ITP [44] . Bowen et al. used a combination of rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) in 20 patients with CLL-associated autoimmune cytopenias-14 patients had complete remission (CR) and 5 patients had partial remission (PR) from their autoimmune cytopenias [30] . Similarly, rituximab in combination with cyclophosphamide and prednisone (R-CP) has also been safe and effective in patients with CLL-associated AIHA refractory to steroids and IVIg [45] . A suggested algorithm to management of AIHA in CLL is shown in Fig. 2 .
Immune Thrombocytopenia
ITP can be difficult to diagnose in CLL patients. It should be considered in patients with CLL who present with thrombocytopenia, especially if they are asymptomatic, do not have concomitant anemia, and if physical examination does not demonstrate significant splenomegaly. Prior to making a diagnosis of CLL-related ITP, it is critical to perform a bone marrow biopsy in order to exclude significant CLL in the marrow that can contribute to thrombocytopenia.
A diagnosis of secondary ITP associated to CLL can be made by the following criteria [10, 16, 30, 31] :
The diagnostic work-up should include a peripheral blood smear and bone marrow evaluation in order to demonstrate that there is sufficient platelet production and in order to exclude any other etiologies. Antiplatelet antibody tests are typically not used in the diagnosis of CLL-related ITP because they are non-specific (positive test results are seen in both immune and non-immune thrombocytopenia) [28] .
Once a diagnosis of ITP is established, treatment is indicated in patients who have platelet counts below 30 × 10 9 /L or who have signs or symptoms of bleeding. The first-line therapy with prednisone at 1 mg/kg per day for approximately 3-4 weeks, followed by a gradual taper over several weeks is the recommended treatment. Approximately half of patients will respond to steroids, which is lower than the response rate seen in patients with primary ITP. In patients who require a more rapid response because of significant bleeding or prior splenectomy, IVIg 1 gm/kg may be given on days 1 and 2. Approximately half of patients will respond to IVIg alone, compared to an approximately 80% response rate to IVIg in patients with primary ITP [16, 35] .
The second-line therapies using monoclonal antibodies with or without the addition of chemotherapy may be considered in patients who do not respond to steroids or IVIg. In patients with fludarabine-associated ITP in CLL, for example, rituximab monotherapy (dosed at 375 mg/m 2 per week for 4 weeks) was found to rapidly increase platelet counts [46, 47] . In addition, a course of rituximab combined with cytotoxic therapy (RCD and R-CVP) has a high rate of response lasting 20-24 months [44, 48] .
Thrombopoietin mimetics (such as romiplostin and eltrombopag) have been shown to be useful compared to standard therapy in primary idiopathic ITP in improving platelet count [49, 50] . These agents have also shown durable responses in patients with refractory CLLassociated ITP and may be considered in patients with minimal CLL disease burden and unremitting severe thrombocytopenia [51, 52] . In a pilot trial of 22 CLL patients with thrombocytopenia (10 patients had CLLassociated ITP and 12 had Rai stage IV CLL), eltrombopag was given at a dose of 75 mg orally daily. The median platelet count was 23 × 10 9 /L. The ORR was 55%, with most responses occurring in the CLLassociated ITP group [53] . Splenectomy can also be an effective treatment option for patients who have relapsed/refractory ITP with CLL. Abbreviations of regimen: RCD rituximab, cyclosphosphamide, dexamethasone; R-CVP rituximab, cyclophosphamide, vincristine, prednisone a Treatment response criteria for autoimmune cytopenia [14] Pure Red Cell Aplasia PRCA should be considered in patients with CLL who present with anemia and reticulocytopenia, albeit it is a rare diagnosis based on the limited information about the prevalence of PRCA in CLL [14] . It is important to rule out other causes of anemia, such as hemolysis, and to evaluate for any vitamin and/or folic acid deficiency [16] . PRCA is characterized by the following criteria [10, 16, 30] :
-Normocytic and normochromic anemia, with Hb <11 gm/ dL, that is otherwise unexplained -Absolute reticulocytopenia -Bone marrow with markedly reduced erythroid precursors with relatively intact leukocyte and megakaryocyte production
All patients suspected to have PRCA due to CLL should undergo a bone marrow examination to demonstrate absent erythroid precursors with intact granulocytic and megakaryocytic lineages [10, 31] . PRCA can also be associated with viral infections, such as EBV, CMV [54] , and human parvovirus B19 [55] . In a large case series of PRCA in CLL (n = 30), parvovirus testing was performed in 24 patients and was noted to be positive in 6 (25%) patients. Of those six patients, parvovirus B19 infection was detected by polymerase chain reaction (PCR) testing in five patients and serologic testing in one patient [29] .
The goal of treatment in secondary PRCA is to recover erythropoiesis and avoid repeated packed red cell transfusions. PRCA secondary to CLL is typically poorly responsive to corticosteroids, although there are isolated case reports of patients with PRCA responding to oral prednisone at 1 mg/kg alone [56] . In patients who have secondary PRCA associated with parvovirus B19, IVIg is typically considered the treatment of choice at a dose of 2 gm/kg usually divided over 5 days (400 mg/kg/day) [57] ; it is thought to neutralize antibodies against the virus [58] . In non-parvovirus-associated PRCA, cyclosporine is most commonly used as either the first-line therapy or after corticosteroids, with a response rate greater than 75% [57] . Prolonged therapy with cyclosporine (>12 months) may be required to maintain remission from PRCA in some instances. Other treatment options using either Fig. 2 Approach to management of AIHA in CLL rituximab alone [59] or in combination with prednisone [29] have also been explored for treatment of PRCA in CLL. Combination therapy with rituximab, cyclophosphamide, and dexamethasone (RCD) had an excellent response in five patients with PRCA, with complete remission in four of five patients; the fifth patient was in second complete remission after a second RCD course [44, 60] .
Autoimmune Granulocytopenia
Secondary autoimmune granulocytopenia in CLL occurs very rarely and can be considered as a diagnosis of exclusion because there are no clear diagnostic criteria. It should be suspected in patients who have isolated neutropenia. It is important to exclude all other causes of granulocytopenia prior to diagnosis, such as evaluating for any cause of secondary immune neutropenia, nutritional deficiencies, and long-term toxicity from prior therapy [16] . The latter is particularly important to exclude; after a median follow-up of 6 years, ∼4% of patients treated on the FCR arm of the CLL8 trial had persistent neutropenia more than 12 months after completing therapy [27] . It is also important to exclude secondary myelodysplasia based on a careful review of the bone marrow biopsy.
Treatment options are not clearly delineated for autoimmune granulocytopenia because of its rarity. Although some cases of autoimmune granulocytopenia can resolve spontaneously without treatment, most patients require therapy with G-CSF or other immunosuppressive medications including corticosteroids and anti-CD20 monoclonal antibodies [14] . Splenectomy may also be considered in refractory patients with limited success [16] .
The Impact of Autoimmune Cytopenias on Outcome in CLL
Regardless of the cause of cytopenia, the two widely accepted Rai and Binet staging systems traditionally placed CLL patients with anemia or thrombocytopenia at an advanced stage of disease with a poorer prognosis [11] . However, the management of CLL is not identical in patients with autoimmune cytopenias vs. cytopenias secondary to bone marrow infiltration. The 1996 NCI-WG and the 2008 IWCLL guidelines acknowledge this issue and suggest treating autoimmune cytopenias in CLL as outlined in the aforementioned sections and reserving CLL-specific therapy only in those patients who do not respond [61] . Despite this clarification, however, the prognostic significance of autoimmune cytopenias secondary to CLL remains unclear.
Several studies demonstrate that autoimmune cytopenias in CLL can be associated with a more aggressive phenotype and worse OS. In a population-based study of 754 CLL patients in British Columbia, Canada, Alzaki et al. [62] identified 80 patients with cytopenias (50 due to extensive bone marrow infiltration and 30 due to autoimmune cytopenias). Although the time to the first CLL therapy was similar between CLL patients who had autoimmune cytopenias and CLL patients without cytopenias (8.2 vs. 8.1 years, p = not significant), median OS was significantly worse for patients with autoimmune cytopenias (8.2 years vs. not reached, p < 0.005) [62] . Moreno et al. [9] presented similar results among 960 unselected CLL patients, of whom 70 (6%) were diagnosed with autoimmune cytopenias during the course of their disease. CLL patients with cytopenias due to bone marrow infiltration had a significantly worse OS compared to patients with cytopenias due to autoimmune complications (3.7 vs. 7.4 years, p = 0.02). Several other studies have reported shorter OS among CLL patients with autoimmune cytopenias compared to patients with cytopenias due to bone marrow infiltration by CLL [63, 64] .
In contrast, isolated studies demonstrate that autoimmune cytopenias do not necessarily predict a worse prognosis in patients with CLL. In an observational study of 132 patients by Kyasa et al. [31] , the survival of CLL patients with autoimmune cytopenias was not statistically different from CLL without autoimmune cytopenias. In a study by Zent et al. [10] , patients with autoimmune cytopenias (n = 75) had a median survival that was not significantly different from patients who did not develop any CLL-related cytopenia, whether from autoimmune cytopenias or bone marrow failure. When compared to patients who presented with cytopenias from bone marrow failure, patients with autoimmune cytopenias had an improved median survival time from onset of cytopenia (median 9.1 vs. 4.4 years, p < 0.001) [10] .
Patients with autoimmune cytopenias are more likely to have advanced Rai stage, older age, high white cell count, short lymphocyte doubling time, unmutated IGVH, and poor risk cytogenetics [15] . Given the contrasting results reported in the literature and the lack of systematic long-term follow-up in many of these studies, it remains unclear if the worse outcome seen in CLL-related autoimmune cytopenias is due to its association with these high-risk biological markers or if it is an independent predictor of shorter OS.
Therapy of Autoimmune Cytopenias in the Era of Novel Agents
The treatment landscape of patients with previously untreated and relapsed/refractory CLL has changed considerably. Oral tyrosine kinase inhibitors, such as ibrutinib (that targets Bruton's tyrosine kinase) and idelalisib (that targets phosphoinositide 3-kinase), are approved for the treatment of CLL patients. Venetoclax, a novel BCL-2 antagonist, was recently approved for the treatment of relapsed CLL with del17p. In general, these agents are extremely efficacious, particularly in the high-risk group of patients (such as those with unmutated IGHV and adverse risk cytogenetics such as del17p and del11q) [65] [66] [67] .
No clinical trials have directly studied the role of these novel signal inhibitors in the management of autoimmune cytopenias in CLL. In a retrospective analysis of 301 CLL patients treated with ibrutinib at Ohio State University Cancer Center [68] , 6 patients developed treatment-emergent autoimmune cytopenias. These episodes of cytopenia did not appear to be temporally related to ibrutinib initiation, occurring within 0.2-23 months after initiation of ibrutinib. Ibrutinib treatment was suspended in four of the six patients, and all patients received appropriate therapy with either prednisone, IVIg, or both. Approximately 25% of patients treated with ibrutinib in this analysis had a past history of autoimmune cytopenias, and 22 (7%) patients were receiving active therapy for their autoimmune cytopenia at the time of ibrutinib initiation. The majority (86%) of patients were successfully able to discontinue concomitant therapy for autoimmune cytopenias after a median of 4.7 months on ibrutinib [68] . In an ad hoc analysis of the phase 3 RESONATE study, which compared ibrutinib vs. ofatumumab in previously treated CLL/ SLL (n = 386), ibrutinib therapy did not precipitate recurrent autoimmune cytopenias in patients with CLL who had a history of autoimmune complications [69] . In another retrospective analysis of 13 CLL patients who were treated with ibrutinib, a flare of the underlying autoimmune cytopenias was observed in 9 (62%) patients during the first weeks of ibrutinib therapy (median time to flare 3 weeks, range 2-8 weeks). The remaining four patients experienced an improvement in the underlying autoimmune cytopenias without a flare. Management of the flare was at the discretion of the treating physician-with some patients receiving corticosteroids and in others the dose of ibrutinib was reduced. The overall response rate to autoimmune cytopenias was 69%, and this paralleled the response rate according to the iwCLL criteria; thereby suggesting that control of the underlying CLL is likely the most effective therapy for the associated secondary autoimmune cytopenias [70] . It is thought that ibrutinib inhibits interleukin-2-inducible kinase (ITK), which could decrease the response of autoreactive T cells, and hence may benefit autoimmune cytopenias in CLL. These studies demonstrate that ibrutinib may be used successfully in CLL patients who have a history of autoimmune cytopenias.
There is limited data on the use of idelalisib in the management of autoimmune cytopenias in CLL. There is a high incidence of autoimmune complications-including autoimmune hepatitis, colitis, and pneumonitis-in idelalisib-treated patients [71, 72] , and therefore until more data become available, it should be avoided in CLL patients who have autoimmune cytopenias. There is no data on the use of venetoclax in patients with autoimmune complications in CLL, although it would not be expected to worsen autoimmune cytopenias.
Conclusion
Our understanding of the mechanisms by which autoimmune cytopenias in CLL occur has evolved considerably since this association was first described by Wasserman et al. [73] more than 60 years ago. Traditional therapy for autoimmune complications in CLL consists of immunosuppression with corticosteroids, and if unsuccessful, treating the underlying CLL. Although useful, chemoimmunotherapy causes profound immunosuppression, which frequently leads to an increased risk of infections and second malignancies, such as myelodysplastic syndrome and Richter's transformation. With the advent of novel agents such as ibrutinib, acalabrutinib, and venetoclax in the armamentarium against CLL, it is hoped that modulation of the immune system will allow for a more targeted approach to managing autoimmune complications in CLL.
